Forminard Elizabeth
SEC CIK 1950802 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | GC, Executive VP | 32.9K | — | $4.09M | 20 | 2023-02-10 | 2026-08-06 |
Most active insiders at JNJ, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Duato Joaquin | CEO, COB, Dir | — | $66.84M |
| 2 | Wolk Joseph J | EVP, CFO | — | $21.77M |
| 3 | REED JOHN C | EVP, Innovative Medicine, R, D | — | $17.29M |
| 4 | Swanson James D. | EVP, CIO | — | $15.11M |
| 5 | Schmid Timothy | EVP, WW COB, MedTech | — | $15.08M |
| 6 | Broadhurst Vanessa | EVP, Gbl Corp Affairs | — | $7.30M |
| 7 | Forminard Elizabeth | EVP, CLO | — | $4.09M |
| 8 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | — | $3.95M |
| 9 | Wengel Kathryn E | EVP, Chief TO, Risk Off | — | $2.41M |
| 10 | Decker Robert J | VP Corp. Ctrl | — | $1.01M |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-07 17:44 | 2026-08-06 | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, CLO | M - OptEx | $131.94 | +9,344 | 32.9K | +40% | +$1.23M |
| DM | 2026-08-07 17:44 | 2026-08-06 | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, CLO | S - Sale+OE | $257.00 | -15.9K | 17.0K | -48% | -$4.09M |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, CLO | M - OptEx | $0.00 | +16.4K | 24.1K | +212% | $0 |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, CLO | F - Tax | $244.41 | -8,361 | 23.6K | -26% | -$2.04M |
| D | 2026-02-06 17:46 | 2026-02-05 | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, CLO | M - OptEx | $129.51 | +8,921 | 21.8K | +69% | +$1.16M |
| D | 2026-02-06 17:46 | 2026-02-05 | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, CLO | F - Tax | $237.90 | -6,226 | 15.5K | -29% | -$1.48M |
| D | 2025-09-03 17:13 | 2025-08-29 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | M - OptEx | $115.67 | +11.5K | 22.4K | +106% | +$1.33M |
| D | 2025-09-03 17:13 | 2025-08-29 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | F - Tax | $177.20 | -9,570 | 12.9K | -43% | -$1.70M |
| DM | 2025-02-18 21:03 | 2025-02-13+ | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | M - OptEx | $0.00 | +3,815 | 11.4K | +51% | $0 |
| DM | 2025-02-18 21:03 | 2025-02-14+ | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | F - Tax | $156.32 | -1,253 | 10.9K | -10% | -$195.9K |
| D | 2024-02-15 16:53 | 2024-02-13 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | M - OptEx | $0.00 | +651 | 8,576 | +8% | $0 |
| D | 2024-02-15 16:53 | 2024-02-13 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | F - Tax | $157.85 | -236 | 8,340 | -3% | -$37.3K |
| DM | 2024-02-14 18:36 | 2024-02-12 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | M - OptEx | $0.00 | +2,859 | 8,959 | +47% | $0 |
| D | 2024-02-14 18:36 | 2024-02-12 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | F - Tax | $157.40 | -1,034 | 7,925 | -12% | -$162.8K |
| D | 2024-02-12 19:24 | 2024-02-08 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | M - OptEx | $0.00 | +979 | 6,463 | +18% | $0 |
| D | 2024-02-12 19:24 | 2024-02-08 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | F - Tax | $156.33 | -363 | 6,100 | -6% | -$56.7K |
| D | 2023-02-15 19:24 | 2023-02-13 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | A - Grant | $0.00 | +2,555 | 6,408 | +66% | $0 |
| D | 2023-02-15 19:24 | 2023-02-13 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | F - Tax | $162.01 | -924 | 5,484 | -14% | -$149.7K |
| D | 2023-02-14 16:35 | 2023-02-10 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | M - OptEx | $0.00 | +1,022 | 4,233 | +32% | $0 |
| D | 2023-02-14 16:35 | 2023-02-10 | JNJ | Johnson & Johnson | Forminard Elizabeth | GC, Executive VP | F - Tax | $162.08 | -380 | 3,853 | -9% | -$61.6K |
Purchase Sale Sale after option exercise All abbreviations